In addition, Foxp3+ Tregs also represent a cell type that is highly relevant for clinical considerations, e.g. for the treatment of autoimmune conditions, graft-versus-host disease (GvHD) and allograft rejection [2–7], and the efficiency of Tregs in decreasing the incidence of acute GvHD in first clinical trials have encouraged further use of these cells in cellular therapies [8]. This evidence concerns the gene FOXP3 and graft versus host disease.